Keywords ISSN accelerated partial breast irradiation boost breast cancer intraoperative radiotherapy late effects quality of life
|
|
- Darren Walters
- 6 years ago
- Views:
Transcription
1 SPECIAL REPORT Intraoperative radiotherapy during breast conserving surgery using a miniature x ray generator (Intrabeam ): theoretical and experimental background and clinical experience Frederik Wenz* 1, Elena Blank 1, Grit Welzel 1, Frank Hofmann 1, Daniela Astor 1, Christian Neumaier 1, Carsten Herskind 1, Axel Gerhardt 2, Marc Suetterlin 2 & Uta Kraus-Tiefenbacher 1 Breast cancer is currently the most frequent indication for intraoperative radiotherapy with increasing numbers worldwide. Intraoperative radiotherapy can be used as a tumor bed boost followed by whole breast radiotherapy, or as a distinct form of accelerated partial breast irradiation in selected patients. This article summarizes the theoretical background including pattern of recurrence and distribution of tumor cell foci in the breast and discusses the rationale for intraoperative radiotherapy, especially using a miniature x ray generator (Intrabeam ). The concepts of how to avoid geographic and temporal miss by giving radiotherapy during surgery to the open wound cavity are described. Experimental and clinical experience is presented based on in vitro experiments and more than 3 treated patients in a single department with mature follow-up. Intraoperative radiotherapy (IORT) has increased tremendously in clinical use and significance with the development of mobile radiotherapy devices (e.g., Liac, Novac 7, Mobetron and Intrabeam ) approximately 1 15 years ago. Breast cancer has become the most frequent indication for IORT over the last decade. Meanwhile, more than 1 centers worldwide use a miniature x ray generator (e.g., Intrabeam, Carl Zeiss Surgical, Oberkochen, Germany) (Figure 1) [1 3] for IORT of early breast cancer during breastconserving surgery (BCS) [11]. This article summarizes the theoretical and experimental background for this approach and presents our clinical experience. Theoretical background BCS followed by external beam radiotherapy (EBRT) to the whole breast has almost completely replaced radical mastectomy in suitable patients. EBRT following BCS using a dose of 5 Gy in standard fractions improves local control, breast cancer-specific survival and overall survival in these patients compared with BCS alone [4]. At present, local recurrence rates of less than 5% after 5 years are typically achievable (Figure 2). Most of the problems, especially acute skin toxicity and late cardiac toxicity have been improved by technical optimizations of dose delivery [5 7]. Nevertheless, in recent years, several studies have questioned the role of standard EBRT to the whole breast in selected patients, because most of the recurrent tumors appeared in the vicinity of the initial tumor bed [2]. It was, therefore, hypothesized that there is a spectrum of breast cancers regarding risk of local recurrence, and that more risk-adapted radiotherapy strategies should be investigated (Figure 3). For high-risk patients (i.e., younger patients, larger tumor and node positivity), it was shown that an additional dose to the tumor bed could improve local control. Therefore, the tumor bed boost is widely accepted as standard of care [8]. For low-risk patients, the situation is still controversial. It was speculated that radiotherapy may be omitted completely in selected patients. However, all randomized studies have shown significantly poorer local control rates when EBRT after BCS was omitted even in low-risk patients (Table 1) [9 12]. At present, several randomized studies are investigating the concept of a limited radiotherapy dose to the tumor bed and its immediate surroundings (e.g., TARGIT [12], ELIOT [13], GEC-ESTRO [13], NSABP B-39 [14]). 1 Department of Radiation Oncology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany 2 Department of Gynecology, University Medical Centre Mannheim, University of Heidelberg, Mannheim, Germany *Author for correspondence: Tel.: Fax: frederik.wenz@umm.de Keywords accelerated partial breast irradiation boost breast cancer intraoperative radiotherapy late effects quality of life part of /WHE Future Medicine Ltd Women's Health (212) 8(1), ISSN
2 SPECIAL REPORT Wenz, Blank, Welzel et al. The concept of temporal miss is based on the fact that a delay of radiotherapy by several weeks reduces local control significantly [15] and that the IORT boost reduces overall treatment time by 1 2 weeks compared with a percutaneous fractionated boost. Furthermore, there is no tumor cell proliferation before and/or during radiotherapy, which can be observed before and during fractionated radiotherapy which is protracted over several weeks and is started several weeks to months after surgery. In addition, there is the theoretical concept of local cure by the IORT boost, which is depicted and explained in Figure 4 [16]. Figure 1. Miniature x ray generator (Intrabeam, Carl Zeiss Surgical, Oberkochen, Germany) in preparation for intraoperative radiotherapy during breast-conserving surgery. Rationale for IORT The elimination of geographic and temporal miss are the two most important advantages of delivering radiotherapy during BCS. Geographic miss is a relevant challenge in day-to-day clinical practice, especially for the localization of the tumor bed boost when radiotherapy is given after chemotherapy, which may last several months, or when oncoplastic reconstruction methods have been used during BCS [14]. Targeting the tumor bed during surgery before oncoplastic reconstruction with the surgeon and radiation oncologist both present in the operating room eliminates this source of reduced local control. Rationale for Intrabeam There is an ongoing controversial debate based on the considerable uncertainty regarding the optimal target volume concepts and the target volume definition for partial breast radiotherapy [17 21]. There are some widely accepted facts, based on systematic pathologic studies, about tumor cell foci outside of the macroscopic tumor [16]. Approximately 4% of all breast cancer patients have no additional disseminated tumor cell foci in the ipsilateral breast. Around 2% have tumor cell foci within a radius of 2 cm and approximately 4% of the patients have tumor cell foci disseminated in the whole breast (Figure 5A). However, this number is certainly lower in patients with small ductal invasive tumors lacking an extensive intraductal component. Regarding the most common histo logical subtype (i.e., ductal invasive carcinoma), it is reasonable to assume that due to the ductal growth and distribution pattern, there is an exponential decline of tumor cell density outside of the macroscopic tumor (Figure 5B). There is obviously no clear border or infiltration zone, and therefore, the classical target volume concept in radiation oncology has to be modified in the case of partial breast radiotherapy. We have, therefore, developed the concept of a sphere of equivalence [16]. This novel target volume concept considers that the dose distribution (i.e., dose fall-off of the Intrabeam) is similar to the decreasing probability of remaining tumor cell foci and the decreasing tumor cell density outside of the macro scopic tumor. Areas of high probability and density are treated with a high dose, whereas areas of low probability and density are treated with a lower dose. Experimental background Traditionally, radiation oncologists are reluctant to apply high single doses, especially to 4 future science group
3 Intraoperative radiotherapy during breast-conserving surgery using Intrabeam SPECIAL REPORT late-reacting tissues such as brain, spinal cord or breast. However, clinical experience from radiosurgery and stereotactic ablative radiotherapy has demonstrated that, as long as the volume is small, high single doses are highly efficient in sterilizing even macroscopic tumors while being well tolerated. There is a special radiobiological situation in IORT with the Intrabeam system regarding the expected normal tissue toxicity [22 24]: A high single dose is delivered with a low dose rate (2 5 min) allowing significant repair in normal tissues during IORT; The dose is limited to a small volume due to the steep dose drop off of 5 kv x rays; The relative biological effectiveness of 5 kv x rays is higher compared with standard 6 MV x rays from linear accelerators. After extensive radiobiological modeling, these results have been experimentally validated [22,23]. One may assume that the chest wall thickness completely shields the lung and heart from relevant radiation doses, and that the skin should be kept at least 5 1 mm away from the applicator to avoid the induction of fibrosis. Clinical experience The clinical experience using low-energy x rays for IORT in breast cancer has now lasted for more than 1 years, when the procedure was pioneered by the Vaidya et al. [3]. Several pilot studies, case series and the randomized Phase III TARGIT trial have been published [25 34]. In this section, we summarize our updated experience regarding the clinical indications for IORT as a boost, IORT as accelerated partial breast irradiation only and IORT during a second BCS in patients with previous radiotherapy to the breast. Cases: Local recurrence-free survival (%) Censored Time after BCS (months) Figure 2. The local recurrence rate in all 337 breast cancer cases undergoing external beam radiotherapy after standard breast-conserving surgery in the Department of Radiation Oncology, University Medical Centre Mannheim (Germany) in the years 25 and 26. Median age: 6 years; 55% T1, 35% T2, 35% N + and 46% chemotherapy. The local recurrence rate was 1.5% after 4 years. BCS: Breast-conserving surgery. future science group Women's Health (212) 8(1) 41
4 SPECIAL REPORT Wenz, Blank, Welzel et al BCS BCS + RT BCS + RT + boost 7 Recurrence rate (%) Risk-adapted de-escalation 2 1 Risk-adapted escalation 5 1 Time after BCS (years) Figure 3. Risk-adapted strategies for radiotherapy after breast-conserving surgery. External beam radiotherapy (EBRT) following breast-conserving surgery reduces the rate of local recurrence at 1 years from 3 4% to approximately 1%. However, 6 7% of the patients would never develop a local recurrence, even without EBRT, and 1% relapse despite EBRT. For low-risk patients, a de-escalation of radiotherapy (e.g., reduction of radiation dose and/or volume) is currently being investigated in Phase III studies. For patients with a high-risk of local recurrence, a dose escalation using a tumor bed boost has been shown to be beneficial. BCS: Breast-conserving surgery; RT: Radiotherapy. Adapted with permission from [4]. IORT as a boost The TARGIT study group (with centers in London, Mannheim, Perth, New York and Aviano) has prospectively treated and followed approximately 3 pilot patients receiving IORT as a tumor bed boost followed by EBRT. It was a group with a relatively high-risk for local recurrence (~3% younger than 5 years of age; ~3% T2 tumors; and ~3% node positive). The median follow-up was more than 5 years. The 5-year local recurrence rate was only approximately 2% [29,31 33], demonstrating the efficacy of this approach. We now have a single center experience of more than 2 patients with a median follow-up of 48 months (Table 2), the local recurrence rate is also in the range of 2%. It is also important to consider the toxicity of a novel approach. We, among others [25,26], have reported that perioperative complications are not increased when prophylactic anti biotics are given. The frequency and volume of postoperative seroma being palpable and visible on imaging studies appeared to be slightly increased after an IORT boost. By contrast, the number of seromas requiring puncture was lower than in a comparable group of patients receiving no IORT [28]. Long-term toxicity was moderate and in the range of the expected rates. Moderate-to-severe fibrosis was not higher than expected. Skin toxicity, including telangiectasias and hyperpigmentation, was in the lower range of comparable studies. Patient satisfaction and quality of life assessments showed very good results [35]. It is of interest for the diagnostic radiologist that imaging changes during followup are different from standard radiotherapy, 42 future science group
5 Intraoperative radiotherapy during breast-conserving surgery using Intrabeam SPECIAL REPORT Table 1. Can we do without external beam radiotherapy after breast-conserving surgery? Trial Author (year) n Criteria Follow-up (years) NSABP B21 Canada CALGB ABCSG 8A Fisher et al. (22) Fyles et al. (24) Hughes et al. (24) Pötter et al. (27) 19 Tumor diameter <1 cm, pn, on TAM 769 Age >5 years, ER +, tumor diameter <2 cm, pn, on TAM 628 Age >7 years, ER +, tumor diameter <2 cm, on TAM 869 Tumor diameter <3 cm, ER +, pn, on TAM/AI IBTR with RT (%) IBTR without RT (%) Ref [9] [11] [1] [12] All randomized trials comparing TAM alone with TAM + external beam radiotherapy in highly selected patients showed significantly inferior local control rates. AI: Aromatase inhibitor; IBTR: In breast tumor recurrence; RT: Radiotherapy; TAM: Tamoxifen. but do not interfere with the detection of recurrences. Imaging changes appear sooner after IORT as compared with external beam. In the long-term, there are comparable rates of imaging changes but more oil cysts and fewer dystrophic calcifications after IORT [36 38]. IORT as accelerated partial breast irradiation only TARGIT was initially given during a pilot phase as a boost to the tumor bed to assess its safety and feasibility, and immediately following this the TARGIT A trial was launched in March 2 [29,31]. IORT alone was initially given in parallel to 8 patients in whom no EBRT was possible [34]. This included patients with comorbidities such as collagen vascular disease or metastases at first presentation. After a follow-up of more than 3 years, the local recurrence rate in these patients was 1.5%. The international prospectively randomized Phase III trial (TARGIT A) recruited more than 22 patients over 1 years [3]. Older patients with small, bioptically verified ductal invasive breast cancer that appeared unifocal on imaging studies were entered. Patients Tumor cell proliferation before and during fractionated radiotherapy Treatment time 6 7 weeks IORT Lower tumor cell number at radiotherapy start after IORT in all patients or local cure in some Treatment time 4.5 weeks Reduction of overall treatment time lowers the in breast tumor recurrence at 5 years by approximately 1 2% Figure 4. The concept of local cure by intraoperative radiotherapy boost. The shortening of the overall treatment time in comparison to external beam radiotherapy including a percutaneous boost by 1 2 weeks reduces the rate of in breast tumor recurrences by approximately 1 2% (reduction of tumor cell proliferation during fractionated radiotherapy). In addition, the application of the tumor bed boost during surgery reduces the number of tumor cells that are present at the beginning of radiotherapy in all patients and even to zero in some patients. One can estimate that an IORT dose of 1 2 Gy will sterilize approximately 3 5% of the remaining tumor stem cells. IORT: Intraoperative radiotherapy. future science group Women's Health (212) 8(1) 43
6 SPECIAL REPORT Wenz, Blank, Welzel et al cm 4.5 cm 4. cm 3.5 cm Patients with foci (%) Dose (Gy) Distance (cm) Distance (cm) Figure 5. The tumor foci probability and tumor cells distribution is mimicked by the dose distribution of Intrabeam (Carl Zeiss Surgical, Oberkochen, Germany). (A) Decreasing percentage of patients with tumor cells at a certain distance. (B) The radial/ductal tumor cell growth pattern leads to an exponential decrease of the tumor cell density with increasing distance from the border of the macroscopic tumor. (C) This behavior is mimicked by the radial drop off of the dose produced by the Intrabeam system. (A) Adapted with permission from [21]. were randomized into the standard arm (BCS followed by EBRT and systemic therapy) or into the risk-adapted experimental arm. These patients received IORT during BCS and when the final histopathological report revealed additional risk factors that were not known before surgery, EBRT was added as per protocol. The first analysis of the trial was published in June 21 and demonstrated a 4-year local recurrence rate of approximately 1% in both arms [3]. The noninferiority criteria for the novel risk-adapted approach were met. In Germany, the inclusion criteria were stricter as compared with other countries, and we have not seen any recurrence in our single-center experience (Table 2). Also, toxicity rates were comparable between both arms. The rate of clinically relevant toxicity was approximately 3% for both approaches. IORT during a second BCS Patients suffering from recurrent breast cancer in a previously irradiated breast (e.g., from previous breast cancer or Hodgkin s disease), are typically recommended to undergo mastectomy even when the second cancer is detected at a Table 2. Rates of ipsilateral breast recurrences after intraoperative radiotherapy during breast-conserving surgery. Treatment n Events 4 years free of IBTR (%) IORT (TARGIT trial) 34 1 IORT (off study) IORT + EBRT Second BCS + IORT (previous RT to breast) Rates are in more than 3 patients with a follow-up of more than 18 months (median follow-up of 48 months). BCS: Breast-conserving surgery; EBRT: External beam radiotherapy; IBTR: In breast tumor recurrence; IORT: Intraoperative radiotherapy; RT: Radiotherapy future science group
7 Intraoperative radiotherapy during breast-conserving surgery using Intrabeam SPECIAL REPORT TARGIT G (German) TARGIT E (elderly) Breast carcinoma, unifocal, ductal invasive, age 5 years, 2 cm tumor diameter Breast carcinoma, unifocal, ductal invasive, age 7 years, 2 cm tumor diameter Wide excision and sentinel node excision and/or axillary dissection + IORT Histopathology: Positive/close margins re-op Extensive intraductal component (>25% of tumor volume) Lymph vessel invasion (L1) Randomization Wide excision and sentinel node excision and/or axillary dissection Whole-breast radiotherapy Wide excision and sentinel node excision and/or axillary dissection + IORT Histopathology: Positive/close margins re-op Extensive intraductal component (>25% of tumor volume) Lymph vessel invasion (L1) Yes No Yes No Whole-breast radiotherapy (4.5 weeks) No further treatment Whole-breast radiotherapy (4.5 weeks) No further treatment Adjuvant systemic therapy Adjuvant systemic therapy Adjuvant systemic therapy Figure 6. Methodology of selected ongoing clinical studies for patients with early breast cancer. IORT: Intraoperative radiotherapy; re-op: Re-operation. very small size. This is based on the expected toxicity of a second course of whole breast radiotherapy. We have offered a second, breastconserving approach with IORT to 22 patients and could demonstrate that conservation of the breast can be achieved in 9% of the cases at 4 year follow-up (Table 2) [39,4]. Conclusion Although there are already several consensus statements of national and international societies regarding the use of accelerated partial breast irradiation only outside of clinical studies (e.g., ASTRO, ASBS, ABR, GEC-ESTRO and DEGRO), the TARGIT study group is currently still offering the possibility to enter patients in the trials to prolong follow-up and to fill additional subprotocols. At the end of May 211, there have been almost 3 patients randomized in the TARGIT A trial. There will be a subanalysis of the German modification ( 5 years, 2 cm), and elderly patients can be entered in the single-arm TARGIT E trial (NCT ) (Figure 6) [15]. Based on the analysis of 76 consecutive patients undergoing BCS from our breast cancer center, we estimated that approximately 96% of the patients are eligible for an IORT boost ( 3.5 cm), future science group Women's Health (212) 8(1) 45
8 SPECIAL REPORT Wenz, Blank, Welzel et al. approximately 35% are eligible for the TARGIT A trial (German version: 5 years, invasive ductal cancer and ct1cn) and 1% qualify for TARGIT E ( 7 years, invasive ductal, ct1cn). Based on these estimations, we see a growing demand for IORT in breast cancer in the future. Future perspective Accelerated partial breast irradiation only using IORT with low-energy photons will become the standard of care for selected patients with early breast cancer, assuming that the noninferiority to EBRT will be demonstrated with mature follow-up. Financial & competing interests disclosure Carl Zeiss Surgical/Oberkochen supports radiobiologial research at the University Medical Centre Mannheim (F Wenz). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Executive summary Intraoperative radiotherapy as a tumor bed boost: the rationale is the lack of geographic and temporal miss. Clinical experience shows very low local recurrence rates with an acceptable rate of side effects. Intraoperative radiotherapy as accelerated partial breast irradiation only : the rationale is the predominance of local recurrences at the initial tumor bed in selected patients. First results from randomized trials demonstrated noninferiority to the standard approach. Further studies are ongoing. References Papers of special note have been highlighted as: of interest of considerable interest 1. Kraus-Tiefenbacher U, Steil V, Bauer L, Melchert F, Wenz F. A novel device for intraoperative radiotherapy (IORT). Onkologie 26, (23). 2. Vaidya JS, Tobias JS, Baum M et al. Intraoperative radiotherapy for breast cancer. Lancet Oncol. 5, (24). 3. Vaidya J, Tobias JS, Baum M et al. Targeted intraoperative radiotherapy (TARGIT) an innovative approach to partial breast irradiation. Semin. Radiat. Oncol. 15, (25). 4. Clarke M, Collins R, Darby S et al.; Early Breast Cancer Trialists Collaborative Group. Effect of radiotherapy and of differences in extent of surgery for early breast cancer on local recurrence and 15 year survival: an overview on randomized trials. Lancet 366, (25). 5. Abo Madyan Y, Polednik M, Rahn A et al. Improving dose homogeneity in large breast by IMRT: efficacy and dosimetric accuracy of different techniques. Strahlenther. Onkol. 184, (28). 6. Lohr F, Heggemann F, Papavassiliu T et al. Ist die kardiotoxizität der radiotherapie im rahmen des brusterhalts überhaupt noch relevant, und könnte sie durch mehrfelder- IMRT gesenkt werden? Strahlenther. Onkol. 185, (29). 7. Lohr F, El-Haddad M, Dobler B et al. Potential impact of a robust and simple IMRT approach for left sided breast cancer on cardiac mortality Int. J. Radiat. Oncol. Biol. Phys. 74, 73 8 (29). 8. Bartelink H, Horiot JC, Poortmans P et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N. Engl. J. Med. 345, (21). 9. Fisher B, Bryant J, Dignam JJ et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J. Clin. Oncol. 2, (22). 1. Hughes KS, Schnaper LA, Berry D et al. Lumpectomy plus Tamoxifen with or without irradiation in women 7 years of age or older with early breast cancer. N. Engl. J. Med. 351, (24). 11. Fyles AW, McCready DR, Manchul LA et al. Tamoxifen with or without breast irradiation in women 5 years of age or older with early breast cancer. N. Engl. J. Med. 351, (24). 12. Pötter R, Gnant M, Kwasny W et al. Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 68, (27). 13. Veronesi U, Orecchia R, Luini A et al. Intraoperative radiotherapy during breast conserving surgery: a study on 1,822 cases treated with electrons. Breast Cancer Res. Treat. 124(1), (21). 14. Benda RK, Yasuda G, Sethi A et al. Breast boost: are we missing the target? Cancer 97, (23). 15. Huang J, Barbera L, Brouwers M et al. Does delay in starting treatment affect the outcomes of radiotherapy? A systematic review. J. Clin. Oncol. 21, (23). 16. Herskind C, Griebel J, Kraus-Tiefenbacher U, Wenz F. Sphere of equivalence a novel target volume concept for intraoperative radiotherapy using low-energy x rays. Int. J. Radiat. Oncol. Biol. Phys. 72, (28). 17. Sautter-Bihl ML, Budach W, Dunst J et al. DEGRO practical guidelines for radiotherapy of breast cancer I. Strahlenther. Onkol. 183, (27). 18. Wenz F, Budach W, Dunst J et al. Accelerated partial breast irradiation (APBI) ready for prime time? Strahlenther. Onkol. 185, (29). 19. Souchon R, Wenz F, Sedlmayer F et al. DEGRO practice guidelines for palliative radiotherapy of metastastic breast cancer. Strahlenther. Onkol. 185, (29). 2. Sautter-Bihl ML, Sedlmayer F, Budach W et al. Intraoperative radiotherapy as accelerated partial breast irradiation for early breast cancer beware of one-stop shops? Strahlenther. Onkol. 186, (21). 21. Holland R, Veling SH, Mravunac M et al. Histologic multifocality of Tis, T1 2 breast carcinomas. Implications for clinical trials of breast-concerving surgery. Cancer 56, (1985). 22. Herskind C, Steil V, Tiefenbacher U, Wenz F. Radiobiologic aspects of intraoperative radiotherapy (IORT) with isotropic low-energy x rays for early-stage breast cancer. Radiat. Res. 163, (25) future science group
9 Intraoperative radiotherapy during breast-conserving surgery using Intrabeam SPECIAL REPORT 23. Herskind C, Schalla S, Hahn EW, Höver KH, Wenz F. Influence of different dose rates on cell recovery and RBE at different spatial positions during protracted conformal radiotherapy. Radiat. Protect. Dosim. 122, (26). 24. Herskind C, Wenz F. Radiobiological comparison of hypofractionated accelerated partial breast irradiation (APBI) and single-dose intraoperative radiotherapy (IORT) with 5-kV x rays. Strahlenther. Onkol. 186, (21). 25. Kraus-Tiefenbacher U, Scheda A, Steil V et al. Intraoperative radiotherapy (IORT) for breast cancer using the INTRABEAM system. Tumori 91, (25). 26. Kraus-Tiefenbacher U, Scheda A, Bauer L, Kehrer T, Melchert F, Wenz F. Intraoperative radiotherapy (IORT) as a boost in patients with early stage breast cancer acute toxicity. Onkologie 29, (26). 27. Kraus-Tiefenbacher U, Bauer L, Scheda A et al. Long-term toxicity of an intraoperative radiotherapy (IORT) boost using low energy x rays during breast conserving surgery (BCS). Int. J. Radiat. Oncol. Biol. Phys. 66, (26). 28. Kraus-Tiefenbacher U, Welzel G, Brade J et al. Postoperative seroma formation after intraoperative radiotherapy (IORT) using low KV x rays given during breast conserving surgery. Int. J. Radiat. Oncol. Biol. Phys. 77, (21). 29. Vaidya J, Baum M, Tobias JS et al. Targeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boost. Int. J. Radiat. Oncol. Biol. Phys. 66, (26). 3. Vaidya JS, Joseph DJ, Tobias JS et al. TARGeted Intraoperative radiotherapy Alone versus whole breast radiotherapy for breast cancer (TARGIT-A trial)- results of an international prospective randomised Phase III trial. Lancet 376, (21). First randomized study on intraoperative radiotherapy (IORT) as accelerated partial breast irradiation in comparison to standard external beam radiotherapy showing noninferiority in 2232 patients. Local recurrence rates in both arms were approximately 1% after 4 years. 31. Vaidya JS, Baum M, Tobias JS et al. Long term results of targeted intraoperative radiotherapy (TARGIT) boost during breast conserving surgery. Int. J. Radiat. Oncol. Biol. Phys. 81(4), (211). Reports the long-term results of IORT as a tumor bed boost with 4 5 years of follow-up. Local recurrence rates were below 2% in a cohort of high-risk patients (~3% node positive and ~3% T2 tumors). 32. Wenz F, Welzel G, Blank E et al. Intraoperative radiotherapy (IORT) as a boost during breast conserving surgery (BCS) using low kv x rays the first five years of experience with a novel approach. Int. J. Radiat. Oncol. Biol. Phys. 77, (21). Reports the long-term results of IORT as a tumor bed boost with 4 5 years of follow-up. Local recurrence rates were below 2% in a cohort of high-risk patients (~3% node positive and ~3% T2 tumors). 33. Blank E, Kraus-Tiefenbacher U, Keller A et al. Single center long term follow-up after intraoperative radiotherapy as a boost during breast-conserving surgery using lowkilovoltage x rays. Ann. Surg. Oncol. 17(Suppl. 3), (21). 34. Keshtgar M, Vaidya JS, Tobias JS et al. Targeted intra-operative radiotherapy (TARGIT) for breast cancer in patients where external beam radiation is not possible. Int. J. Radiat. Oncol. Biol. Phys. 8, (211). 35. Welzel G, Hofmann F, Blank E et al. Health related quality of life after breast conserving surgery and intraoperative radiotherapy for breast cancer using low-kilovolt x rays. Ann. Surg. Oncol. 17(Suppl. 3), (21). 36. Wasser K, Schoeber C, Kraus-Tiefenbacher U et al. Early mammographic and sonographic findings after intraoperative radiotherapy (IORT) as a boost in patients with breast cancer. Eur. J. Radiol. 17, (27). 37. Ruch M, Brade J, Schoeber C et al. Long-term follow-up findings in mammography and ultrasound after intraoperative radiotherapy (IORT) for breast cancer. Breast 18, (29). 38. Wasser K, Ruch M, Brade J et al. Do structural changes in the tumor bed after intraoperative radiotherapy (IORT) of breast cancer complicate the evaluation of mammograms in a long-term follow-up? Eur. J. Radiol. doi:1.116/j. ejrad (211) (Epub ahead of print). 39. Kraus-Tiefenbacher U, Bauer L, Schöber C, Schaefer J, Steil V, Wenz F. Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy. BMC Cancer 7, 178 (27). 4. Kraus-Tiefenbacher U, Blank E, Wenz F. Intraoperative Radiotherapy (IORT) during a second breast-conserving procedure for relapsed breast cancer after previous external beam radiotherapy (EBRT). Int. J. Radiat. Oncol. Biol. Phys. 8, (211). Websites 11. Targeted intraoperative radiotherapy (IORT) for breast cancer: intrabeam The Clinical Trials Group, University College London Groupe Européen de Curietherapie (GEC), European Society for Therapeutic Radiology and Oncology (ESTRO). GEC ESTRO APBI Trial Radiation Therapy Oncology Group (RTOG). RTOG 413 Protocol Information. StudyDetails.aspx?study= ClinicalTrials.gov. Prospective Phase II Study of Intraoperative Radiotherapy (IORT) in Elderly Patients With Small Breast Cancer (TARGIT E). NCT future science group Women's Health (212) 8(1) 47
New Technologies in Radiation Oncology. Catherine Park, MD, MPH Advocate Good Shepherd Hospital
New Technologies in Radiation Oncology Catherine Park, MD, MPH Advocate Good Shepherd Hospital Breast Radiation Early Stage Breast Cancer Whole Breast Radiation Delivered to the whole breast Boost to the
More informationKeynote Address at the American Society of Breast Surgeons 18th Annual Meeting
Ann Surg Oncol (2017) 24:2811 2817 DOI 10.1245/s10434-017-5942-z ORIGINAL ARTICLE BREAST ONCOLOGY Keynote Address at the American Society of Breast Surgeons 18th Annual Meeting Current and Future Application
More informationIntraoperative. Radiotherapy
Intraoperative Radiotherapy ROBERTO ORECCHIA UNIVERSITY of MILAN & EUROPEAN INSTITUTE of ONCOLOGY & CNAO FOUNDATION Breast Cancer Brescia, 30th September 2011 IORT, very selective technique to intensify
More informationConsensus Guideline on Accelerated Partial Breast Irradiation
Consensus Guideline on Accelerated Partial Breast Irradiation Purpose: To outline the use of accelerated partial breast irradiation (APBI) for the treatment of breast cancer. Associated ASBS Guidelines
More informationIntraoperative radiotherapy for breast cancer. Information for patients on IORT boost treatment
Intraoperative radiotherapy for breast cancer Information for patients on IORT boost treatment 1 No reason for despair Patients go through a period of great anxiety and apprehension when breast cancer
More informationINTRABEAM System from ZEISS Targeted Radiotherapy
INTRABEAM System from ZEISS Targeted Radiotherapy The moment radiotherapy can be ideally tailored to the needs of your patient. This is the moment we work for. // INNOVATION MADE BY ZEISS 2 3 4 Targeted
More informationSeptember 9, IORT Shows Promise in Early Use
An actual intraoperative delivery; a Xoft unit is attached to a balloon ready for treatment. September 9, 2011 IORT Shows Promise in Early Use A look at techniques and appropriate uses for this emerging
More informationRadiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationIntraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 2 TARGIT
Ann Surg Oncol (2014) 21:3793 3799 DOI 10.1245/s10434-014-3999-5 REVIEW ARTICLE BREAST ONCOLOGY Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 2 TARGIT Melvin
More informationRADIOTHERAPY IN BREAST CANCER :
RADIOTHERAPY IN BREAST CANCER : PAST, PRESENT, FUTURE Dr Jyotirup Goswami Consultant Radiation Oncologist Narayana Cancer Institute Narayana Superspecialty Hospital Breast cancer is the classic paradigm
More informationObjectives Intraoperative Radiation Therapy for Early Stage Breast Cancer
Objectives Intraoperative Radiation Therapy for Early Stage Breast Cancer Cristina Lopez-Peñalver, MD, FACS October 11, 2014 Disclosures I have no relevant commercial relationships to disclose. Discuss
More informationRecent Advances in Breast Cancer Treatment
Recent Advances in Breast Cancer Treatment Pornchai O-charoenrat MD, PhD, FRCST, FICS Professor Chief, Division of Head-Neck & Breast Surgery Department of Surgery, Siriraj Hospital, THAILAND Recent Advances
More informationBREAST CANCER IOeRT RATIONALE
BREAST CANCER IOeRT RATIONALE Approximately 80% of the breast tumor recurrences origins at the site of the original disease. These data suggest that the majority of breast tumor recurrences result from
More informationPartial Breast Irradiation for Breast Conserving Therapy
To Radiate or Not? Is APBI the Right Compromise Solution? Partial Breast Irradiation for Breast Conserving Therapy Julia White MD Professor, Radiation Oncology Agenda Role of radiotherapy in breast conservation
More informationIORT What We ve Learned So Far
IORT What We ve Learned So Far The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation
More informationIntra operative Intrabeam radiation for breast cancer
Intra operative Intrabeam radiation for breast cancer Dr Gillian Campbell Radiation Oncologist May 2018 Disclaimer/Conflicts I am a radiation oncology consultant at Christchurch Hospital, Canterbury Breast
More informationAccelerated partial breast irradiation: state of the art
Accelerated partial breast irradiation: state of the art P.A. Coucke, N. Jansen, L. Jánváry, C. Louis, J. Vanderick, A. Rorive, J. Collignon, E. Lifrange, S. Maweja, G. Jerusalem Accelerated partial breast
More informationA cohort analysis to identify eligible patients for intraoperative radiotherapy (IORT) of early breast cancer. Sperk et al.
A cohort analysis to identify eligible patients for intraoperative radiotherapy (IORT) of early breast cancer Sperk et al. Sperk et al. Radiation Oncology 2014, 9:154 Sperk et al. Radiation Oncology 2014,
More informationIn vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost
Original Article Radiat Oncol J 2017;35(2):121-128 https://doi.org/10.3857/roj.2017.00150 pissn 2234-1900 eissn 2234-3156 In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative
More informationHypofractionated Radiotherapy for breast cancer: Updated evidence
2 rd Bangladesh Breast Cancer Conference, Dhaka, December 2017 Hypofractionated Radiotherapy for breast cancer: Updated evidence Tabassum Wadasadawala Associate Professor of Radiation Oncology Tata Memorial
More informationInitial experience of intraoperative radiotherapy as tumour bed boost after neoadjuvant chemotherapy in breast cancer patients
Original Article Initial experience of intraoperative radiotherapy as tumour bed boost after neoadjuvant chemotherapy in breast cancer patients Saskia Spaich 1, Benjamin Tuschy 1, Elena Sperk 2, Frederik
More informationBreast Conservation Therapy
May 18, 2018 Breast Conservation Therapy One Treatment No Longer Fits All Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. Define stages of breast cancer that are candidates
More informationACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER
ACCELERATED BREAST IRRADIATION EVOLVING PARADIGM FOR TREATMENT OF EARLY STAGE BREAST CANCER KHANH NGUYEN, MD, MA DEPARTMENT OF RADIATION ONCOLOGY BAYHEALTH CANCER CENTER BREAST CANCER STATISTICS Most common
More informationdoi: /j.ijrobp
doi:10.1016/j.ijrobp.2009.12.047 Int. J. Radiation Oncology Biol. Phys., Vol. 79, No. 4, pp. 977 984, 2011 Copyright Ó 2011 Elsevier Inc. Printed in the USA. All rights reserved 0360-3016/$ see front matter
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 27 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationAcute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols
ORIGINAL ARTICLES Acute and late adverse effects of breast cancer radiation: Two hypo-fractionation protocols Mohamed Abdelhamed Aboziada 1, Samir Shehata 2 1 Department of Radiation Oncology, South Egypt
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Accelerated Breast Irradiation and Brachytherapy Boost Page 1 of 23 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Accelerated Breast Irradiation and Brachytherapy
More informationReview Article Intraoperative Radiotherapy for Breast Cancer: The Lasting Effects of a Fleeting Treatment
International Journal of Breast Cancer, Article ID 214325, 12 pages http://dx.doi.org/10.1155/2014/214325 Review Article Intraoperative Radiotherapy for Breast Cancer: The Lasting Effects of a Fleeting
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationBreast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
More informationLow-Kilovoltage, Single-Dose Intraoperative Radiation Therapy for Breast Cancer: Results and Impact on a Multidisciplinary Breast Cancer Program
Low-Kilovoltage, Single-Dose Intraoperative Radiation Therapy for Breast Cancer: Results and Impact on a Multidisciplinary Breast Cancer Program Stephen R Grobmyer, MD, FACS, Judith L Lightsey, MD, Curtis
More informationCorporate Medical Policy
Corporate Medical Policy Breast Brachytherapy for Accelerated Partial Breast Radiotherapy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: breast_brachytherapy_for_accelerated_partial_breast_radiotherapy
More informationCurrent Status of Accelerated Partial Breast Irradiation. Julia White MD Professor, Radiation Oncology
Current Status of Accelerated Partial Breast Irradiation Julia White MD Professor, Radiation Oncology I have no disclosures relative to the presented material Agenda ABPI Timeline APBI by Method Clinical
More informationWhole Breast Irradiation: Class vs. Hypofractionation
Whole Breast Irradiation: Class vs. Hypofractionation Kyung Hwan Shin, MD, PhD. Dept. of Radiation Oncology, Seoul National University Hospital 2018. 4. 6. GBCC Treatment Trends of Early Breast Cancer
More informationRadiotherapy Physics and Equipment
Radiological Sciences Department Radiotherapy Physics and Equipment RAD 481 Lecture s Title: Introduction Dr. Mohammed EMAM Ph.D., Paris-Sud 11 University Vision :IMC aspires to be a leader in applied
More informationEARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT
May 13, 2016 EARLY STAGE BREAST CANCER AND THE EMERGING ROLE OF IORT Presenter: Paul B. Fowler, MD Radiation Oncology, MGSH/MUMH 1 Objectives: 1. List treatment options for early stage breast cancer. 2.
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationAccelerated Partial Breast Irradiation
Accelerated Partial Breast Irradiation OSCO/OU Stephenson Cancer Center Saturday, March 5, 2016 Robert Kuske, MD, FAACE Founder, Medical Director Arizona Breast Cancer Specialists Scottsdale, Arizona 1
More informationTrends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States
Trends in the Use of Implantable Accelerated Partial Breast Irradiation Therapy for Early Stage Breast Cancer in the United States A THESIS SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL OF THE UNIVERSITY
More informationSlide 1. Slide 2. Slide 3. Introduction of INTRABEAM IORT. Disclosure. Contents. I have nothing to disclose.
Slide 1 AAPM 2017 Introduction of INTRABEAM IORT Hualin Zhang, Ph.D. Dept of Radiation Oncology, Northwestern University, Northwestern Memorial Hospital, Chicago, Illinois August 2, 2017 Slide 2 Disclosure
More informationPartial Breast Irradiation using adaptive MRgRT
Partial Breast Irradiation using adaptive MRgRT Shyama Tetar, radiation-oncologist VUmc Amsterdam 15-12-2017 5 th Vumc SBRT symposium 2017 Current practice Breast conserving treatment (BCT) Breast conserving
More informationc, Jw, xj
Received: 2 January 2017 Revised: 21 April 2017 Accepted: 11 June 2017 DOI: 10.1002/acm2.12140 RADIATION ONCOLOGY PHYSICS Therapeutic analysis of Intrabeam-based intraoperative radiation therapy in the
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationCarol Marquez, M.D. Department of Radiation Medicine OHSU
Carol Marquez, M.D. Department of Radiation Medicine OHSU Describe partial breast irradiation (PBI) and discuss why it is being used. Detail methods of performing partial breast irradiation. Explain how
More informationCommissioning and Radiobiology of the INTRABEAM System
Commissioning and Radiobiology of the INTRABEAM System Susha Pillai and Junan Zhang Scheme INTRABEAM System. Physics Commissioning, QA, and Radiation Protection Radiobiology 1 Disclosure OHSU is an INTRABEAM
More informationHealth technology description. Key points. Epidemiology. Clinical effectiveness
In response to an enquiry from the Scottish Radiotherapy Advisory Group Number 35 May 2011 N The clinical and cost effectiveness of the use of brachytherapy to treat breast cancer Health technology description
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More informationPavel ŠLAMPA, Jana RUZICKOVA, Barbora ONDROVA, Hana TICHA, Hana DOLEZELOVA
Sole conformal perioperative interstitial brachytherapy of early stage breast carcinoma using high-dose rate afterloading: longer-term results and toxicity Received: 0.09.2007 Accepted: 7.02.2008 Subject:
More informationBreast Cancer. What is breast cancer?
Scan for mobile link. Breast Cancer Breast cancer is a malignant tumor in or around breast tissue. It usually begins as a lump or calcium deposit that develops from abnormal cell growth. Most breast lumps
More informationRecent Advances in Breast Radiotherapy
Recent Advances in Breast Radiotherapy Dr Anna Kirby Consultant Clinical Oncologist 2 The Royal Marsden Overview: Key innovations 1. 2D to 3D planning 2. Hypofractionation 3. Intensity modulated radiotherapy
More informationBy Rufus Mark, MD, Gail Lebovic, MD, Valerie Gorman, MD, Oscar Calvo, PhD. TABLE 1 EARLY STAGE BREAST CANCER RANDOMIZED TRIALS M vs.
EVOLUTION OF BREAST CONSERVATION RADIATION TREATMENT TECHNIQUES IN BREAST CANCER : FROM 6 WEEKS TO 3 WEEKS TO 1 WEEK TO 1 DAY AND FROM WHOLE BREAST TO PARTIAL BREAST By Rufus Mark, MD, Gail Lebovic, MD,
More informationProtocol of Radiotherapy for Breast Cancer
107 年 12 月修訂 Protocol of Radiotherapy for Breast Cancer Indication of radiotherapy Indications for Post-Mastectomy Radiotherapy (1) Axillary lymph node 4 positive (2) Axillary lymph node 1-3 positive:
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2013 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationCommentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement"
Practical Radiation Oncology (2017) xx, xxx xxx www.practicalradonc.org Commentary on "Accelerated partial breast irradiation consensus statement: Update of an ASTRO Evidence-Based Consensus Statement"
More informationAccelerated Radiation Treatment for Early Stage Breast Cancer. update and perspective
Accelerated Radiation Treatment for Early Stage Breast Cancer update and perspective School of Breast Oncology Atlanta, 11/2012 Douglas W. Arthur, M.D. Professor Traditional Whole Breast Irradiation WBI
More informationTechnology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta501
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer Technology appraisal guidance Published: 31 January 2018 nice.org.uk/guidance/ta501 NICE 2018. All rights reserved. Subject to
More informationSurgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery
Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation
More informationPrinciples of breast radiation therapy
ANZ 1601/BIG 16-02 EXPERT ESMO Preceptorship Program 2017 Principles of breast radiation therapy Boon H Chua Professor Director of Cancer and Haematology Services UNSW Sydney and Prince of Wales Hospital
More informationReview Article Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single Center Experiences
International Breast Cancer, Article ID 637898, 6 pages http://dx.doi.org/10.1155/2014/637898 Review Article Intraoperative Boost Radiotherapy during Targeted Oncoplastic Breast Surgery: Overview and Single
More informationGrit Welzel 1*, Angela Boch 1, Elena Sperk 1, Frank Hofmann 1, Uta Kraus-Tiefenbacher 1, Axel Gerhardt 2, Marc Suetterlin 2 and Frederik Wenz 1
Welzel et al. Radiation Oncology 2013, 8:9 RESEARCH Open Access Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with
More informationIntraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1 ELIOT
Ann Surg Oncol (2014) 21:3787 3792 DOI 10.1245/s10434-014-3998-6 REVIEW ARTICLE BREAST ONCOLOGY Intraoperative Radiation Therapy: A Critical Analysis of the ELIOT and TARGIT Trials. Part 1 ELIOT Melvin
More informationRadiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
- Original Issue Date (Created): November 22, 2011 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationIs Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group
Is Breast Radiation Therapy Necessary in the Elderly? Cancer and Leukemia Group B Radiation Therapy Oncology Group Eastern Cooperative Oncology Group CALGB 9343 Submitted 1990 Opened July 15, 1994 Closed
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationSan Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy
More informationCPT Codes: 77424, Last Review Date: July 2017 Guideline Number: NIA_CG_226 Last Revised Date: July 2017 Responsible Department:
Magellan Healthcare Clinical guideline: INTRAOPERATIVE RADIATION THERAPY (IORT) Original Date: November 2013 Page 1 of 5 CPT Codes: 77424, 77425 Last Review Date: July 2017 Guideline Number: NIA_CG_226
More informationSSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer
SSO-ASTRO Consensus Guidance Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer Dr. Yvonne Tsang St. Paul s Hospital Introductions Breast-conserving
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationAdvances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015
Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy
More informationClinical experience with TomoDirect System Tangential Mode
Breast Cancer Clinical experience with TomoDirect System Tangential Mode European Institute of Oncology Milan, Italy Disclosure & Disclaimer An honorarium is provided by Accuray for this presentation The
More informationIntraoperative radiotherapy (IORT) refers to the application
Intraoperative Electrons Roberto Orecchia, MD* and Umberto Veronesi, MD Intraoperative radiotherapy (IORT) has been used for many years for treating patients with various locally-advanced malignancies,
More informationClinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience
Original Article Clinical outcomes of patients treated with accelerated partial breast irradiation with high-dose rate brachytherapy: Scripps Clinic experience Rachel Murray 1, Fantine Giap 2, Ray Lin
More informationpat hways Medtech innovation briefing Published: 24 August 2016 nice.org.uk/guidance/mib76
pat hways Axxent brachytherapy system for early stage breast cancer Medtech innovation briefing Published: 24 August 2016 nice.org.uk/guidance/mib76 Summary The technology described in this briefing is
More informationDisclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
More informationCancer. Savita Dandapani
New Modalities for Breast Cancer Savita Dandapani Disclosures Accuray Talk at ASTRO 10/2015. Xoft provided slides for the partial breast radiation equipment. Early Stage: Deep Inspiratory Breath Hold (DIBH)
More informationHypofractionated radiotherapy for breast cancer: too fast or too much?
Editorial Hypofractionated radiotherapy for breast cancer: too fast or too much? Vassilis E. Kouloulias 1, Anna G. Zygogianni 2 1 2nd Department of Radiology, Radiotherapy unit, Attikon University Hospital,
More informationIntraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience
IORT for breast cancer Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience Roberto Orecchia 1,2, Maria Cristina Leonardi 1, Patrick
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationBrachytherapy: The precise answer for tackling breast cancer. Because life is for living
Brachytherapy: The precise answer for tackling breast cancer Because life is for living Table of contents Executive summary 3 Introduction 4 Management of early stage breast cancer 5 Radiotherapy options
More informationGuidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017
Guidelines for the treatment of Breast cancer with radiotherapy v.1.0 September 2017 Author: Dr Virginia Wolstenholme, Consultant Clinical Oncologist, Barts Health Date agreed: September 2017 Date to be
More information1 Department of Radiation Oncology 2 Department of Surgery 3 Department of Pathology and Laboratory Medicine
with Tumor Bed Brachytherapy Alone in Stage I Breast Cancer: Results of a Phase II Trial Leela Krishnan M.S., M.D., F.A.C.R.O. 1, William R. Jewell, M.D., F.A.C.S. 2, Carol Connor, M.D. 2, Ossama W. Tawfik,
More informationAccelerated Partial Breast Irradiation: A Review and Description of an Early North American Surgical Experience With the Intrabeam Delivery System
A variety of techniques for accelerated partial breast irradiation are available. Photo courtesy of Lisa Scholder. Hidden Power, 24ʺ 28ʺ. Accelerated Partial Breast Irradiation: A Review and Description
More informationNETSCC, HTA 7th October 2010
NETSCC, HTA 7 th October 2010 TARGeted Intraoperative radiotherapy vs. Post Operative Radiotherapy An international randomised controlled trial to compare targeted intraoperative radiotherapy with conventional
More informationAdvances in Localized Breast Cancer
Advances in Localized Breast Cancer Melissa Camp, MD, MPH and Fariba Asrari, MD June 18, 2018 Moderated by Elissa Bantug 1 Advances in Surgery for Breast Cancer Melissa Camp, MD June 18, 2018 2 Historical
More informationArticles. Vol 383 February 15,
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: -year results for local control and overall survival from the TARGIT-A randomised trial Jayant S Vaidya,
More informationAccelerated Partial Breast Irradiation. Dr Patricia Lillis MD, MHA,MSS Marshfield Clinic Radiation Oncology
Accelerated Partial Breast Irradiation Dr Patricia Lillis MD, MHA,MSS Marshfield Clinic Radiation Oncology Outline 1. Rationale 2. Review of selected literature 3. Technical aspects 4. Selection criteria
More informationOral cavity cancer Post-operative treatment
Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection
More informationWhat are Adequate Margins of Resection for Breast-Conserving Therapy?
What are Adequate Margins of Resection for Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School What are Adequate Margins
More informationContributo della medicina nucleare nei tumori mammari: dal linfonodo sentinella alla IART
Contributo della medicina nucleare nei tumori mammari: dal linfonodo sentinella alla IART Prof. Giovanni Paganelli Dipartimento delle procedure e tecnologie avanzate, IRST-IRCCS Meldola. Universita degli
More informationWhy Choose Brachytherapy and Not External Beam RT or IORT?
May 30 31, 2014 Miami Beach, FL USA Why Choose Brachytherapy and Not External Beam RT or IORT? Csaba Polgár, MD, PhD, MSc National Institute of Oncology Budapest, Hungary 1 Disclosure Csaba Polgár, MD,
More informationPost-Lumpectomy Radiation Techniques and Toxicities
Post-Lumpectomy Radiation Techniques and Toxicities Laura Willson, MD Abbott Northwestern Hospital Dept. of Radiation Oncology February 2, 2019 Learning Objectives How radiation therapy works Standard
More informationAccelerated Partial Breast Irradiation: Potential Roles Following Breast-Conserving Surgery
APBI is a promising technique in selected patients with early-stage breast cancer, but further study is needed on outcome and toxicity associated with this approach. Nick Patten. Passing Light (detail).
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationThe Role of a Boost Radiation Dose in Patients with Negative Re-Excision Findings
24 The Open Breast Cancer Journal, 2011, 3, 24-28 Open Access The Role of a Boost Radiation Dose in with Negative Re-Excision Melanie C. Smitt and Kathleen C. Horst * Department of Radiation Oncology,
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationBreast Cancer. What is breast cancer?
Scan for mobile link. Breast Cancer Breast cancer is a malignant tumor in or around breast tissue. It usually begins as a lump or calcium deposit that develops from abnormal cell growth. Most breast lumps
More informationComparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer
Original article Original articles Comparison of two techniques of interstitial pulsed dose rate boost brachytherapy in conservative treatment of breast cancer Krystyna Serkies, MD, PhD 1, Zofia Tarnawska,
More information